A new approach to managing intraductal papillary mucinous pancreatic neoplasms

Top Cited Papers
Publisher Website
Google Scholar
Abstract
A large prospective study by Salvia et al1 published in this issue of Gut shows that a follow-up protocol for branch duct intraductal papillary mucinous neoplasms (IPMNs) appears feasible and safe (see page 1086). IPMNs of the pancreas were originally described in a number of case reports and short series of patients in the early 1990s,2,3 and mucinous cystic neoplasms of the pancreas had been reported in the 1980s.4–6 In 1996 the World Health Organisation (WHO) revised the criteria for the pathological diagnosis of IPMN,7 thus allowing the differentiation of IPMN from other mucinous/cystic neoplasms of the pancreas. This meant that a number of “different” neoplasms could now come under the single diagnostic umbrella of IPMN (table 1).